Migliorini F, Kader N, Eschweiler J, Tingart M, Maffulli N. Platelet-rich plasma versus steroids injections for greater trochanter pain syndrome: a systematic review and meta-analysis.
Br Med Bull 2021;
139:86-99. [PMID:
34405857 DOI:
10.1093/bmb/ldab018]
[Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/03/2021] [Revised: 07/17/2021] [Accepted: 07/20/2021] [Indexed: 11/12/2022]
Abstract
INTRODUCTION
Greater trochanter pain syndrome (GTPS) is characterized by a persistent and debilitating pain around the greater trochanter. GTPS can be caused by a combination of gluteus medius or minimus tendinopathy, snapping hip or trochanteric bursitis.
SOURCE OF DATA
Recent published literatures identified from PubMed, EMBASE, Google Scholar, Scopus.
AREAS OF AGREEMENT
Platelet rich plasma (PRP) and corticosteroids (CCS) injections are useful options to manage symptoms of GTPS.
AREAS OF CONTROVERSY
Whether PRP leads to superior outcomes compared to CCS injections is unclear.
GROWING POINTS
A systematic review and meta-analysis comparing PRP versus CCS in the management of GTPS was conducted.
AREAS TIMELY FOR DEVELOPING RESEARCH
PRP injections are more effective than CCS at approximately 2 years follow-up.
Collapse